Skip to main content
. 2022 Jul 11;12:899987. doi: 10.3389/fonc.2022.899987

Figure 1.

Figure 1

USP13 is overexpressed in SCLC and predicts poor clinical outcomes. (A) Kaplan-Meier analysis of overall survival curves from a public dataset (GSE60052) for SCLC patients with low or high USP13 expression. p values are calculated using a log-rank test (two-tailed). (B, C) Immunohistochemical analysis of USP13 in SCLC tumor specimens (T) and their adjacent normal tissues (N). Representative IHC images are shown (B). IHC scores of USP13 expression were calculated (C). Scale bars: 500 µm. Data represent the means ± SD of samples. Two-tailed student’s t-test was used. ***p < 0.001. (D) The expression of USP13 in SCLC patients with or without lymph node metastasis is shown. Data represent the means ± SD of samples. Two-tailed student’s t-test was used. **p < 0.01. (E) USP13 expression levels are shown in SCLC patients of different cancer stages. Data represent the means ± SD of samples. Two-tailed student’s t-test was used. ***p < 0.001. (F) The Kaplan–Meier method with a two-tailed log-rank test was used to plot survival curves for SCLC patients with high and low USP13 expression.